Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
300 participants
OBSERVATIONAL
2006-12-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacogenomics of Paclitaxel in Ovarian Cancer
NCT00415181
Oxford Ovarian Cancer Predict Chemotherapy Response 01
NCT01770535
A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer
NCT02026921
Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
NCT00897806
Search for Predictors of Therapeutic Response in Ovarian Carcinoma
NCT01391351
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
We will use tissue from patients who participated in one of two clinical trials that are both closed for inclusion. Genotypic data from this tissue will be correlated with toxicity and survival data drawn from a research database. We expect to be able to find \>300 available cases to study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients enrolled in "OVAR-9" in Denmark, Sweden or Norway
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Danish Clinical Intervention Research Academy
OTHER
Ministry of the Interior and Health, Denmark
OTHER_GOV
University of Southern Denmark
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of Southern Denmark
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kim Brøsen, phd
Role: STUDY_DIRECTOR
University of Southern Denmark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Pharmacology, University of Southern Denmark
Odense, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bergmann TK, Green H, Brasch-Andersen C, Mirza MR, Herrstedt J, Holund B, du Bois A, Damkier P, Vach W, Brosen K, Peterson C. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol. 2011 Jul;67(7):693-700. doi: 10.1007/s00228-011-1007-6. Epub 2011 Feb 16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WRAMC WU# 04-23009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.